Q-omics provides the consensus-scored MIR4322 profile across patient tissues and cancer cell-line models. MIR4322 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR4322 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, MIR4322 RNA expression shows 12,440 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUAD, and THYM as cancer lineages where MIR4322 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4322 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4322 survival associations across molecular data types. MIR4322 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4322 RNA expression–survival associations across cancer types. High MIR4322 expression shows unfavorable associations in KIRP, KICH, BLCA and LIHC, but favorable associations in HNSC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR4322 RNA expression.
This table summarizes MIR4322 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4322. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4322 shows lower tumor expression in LUAD, COAD, KIRC, UCEC, LUSC and BRCA. The LUAD box plot shows higher MIR4322 RNA expression in normal versus tumor tissue (log2 FC = −0.532, t-test p < 0.001).
This table shows molecular features associated with MIR4322 in patient tissues and cancer cell lines. In patient samples, MIR4322 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
